Roisin E. O'Cearbhaill reviews a phase 1/2 trial evaluating REGN5668, a MUC16×CD28 bispecific antibody, in combination with other targeted therapies for recurrent ovarian and endometrial cancers.
Roisin O’Cearbhaill, MD
Advertisement
Roisin O’Cearbhaill, MD, is a medical oncologist with a primary focus on the medical treatment of patients with gynecologic cancers at Memorial Sloan Kettering Cancer Center.
Articles by Roisin O’Cearbhaill, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Late-Breaking Phase 3 Data Headline ESMO 2026 Presidential Symposium I
2
Personalized mRNA Vaccine Intismeran Plus Pembro Cuts Melanoma Recurrence
3
Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
4
Sunvozertinib Now Available in US for EGFR Exon 20 Insertion NSCLC
5